SalaryGuide
AboutPricingFor Employers

Marketing jobs

7 marketing jobs

Natera logo
2 months ago

Director, Media Relations and Communications

Natera

USA (Remote)Full time$166K/yr – $207K/yr
Natera logo
2 months ago

Senior Area Marketing Manager, Women’s Health - Southeast

Natera

USA (Remote)Full time$162K/yr – $202K/yr
Natera logo
2 months ago

Marketing Analytics Manager

Natera

California, MO (Remote)Full time$116K/yr – $145K/yr
Natera logo
3 months ago

Digital Marketing Specialist/Coordinator

Natera

USA (Remote)Temporary$31/hr – $38/hr
Natera logo
3 months ago

Email Marketing Specialist

Natera

USA (Remote)Temporary$43/hr – $57/hr
Natera logo
3 months ago

Sr Area Marketing Manager, Oncology (Northeast)

Natera

USA (Remote)Full time$122K/yr – $153K/yr
Natera logo
4 months ago

Sr. Marketing Manager, Health Systems

Natera

USA (Remote)Full time$134K/yr – $167K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

7 jobs
Natera logo

Director, Media Relations and Communications

Natera

USA (Remote)

$166K/yr - $207K/yrIn-houseFull-timeDirector/executive8+ years exp.
2 months ago
Natera logo

Senior Area Marketing Manager, Women’s Health - Southeast

Natera

USA (Remote)

$162K/yr - $202K/yrIn-houseFull-timeSenior level3+ years exp.
2 months ago
Natera logo

Marketing Analytics Manager

Natera

California, MO (Remote)

$116K/yr - $145K/yrIn-houseFull-timeMid level5+ years exp.
2 months ago
Natera logo

Digital Marketing Specialist/Coordinator

Natera

USA (Remote)

$31/hr - $38/hrIn-houseTemporaryEntry level2+ years exp.
3 months ago
Natera logo

Email Marketing Specialist

Natera

USA (Remote)

$43/hr - $57/hrIn-houseTemporaryMid level2+ years exp.
3 months ago
Natera logo

Sr Area Marketing Manager, Oncology (Northeast)

Natera

USA (Remote)

$122K/yr - $153K/yrIn-houseFull-timeSenior level5+ years exp.
3 months ago
Natera logo

Sr. Marketing Manager, Health Systems

Natera

USA (Remote)

$134K/yr - $167K/yrIn-houseFull-timeSenior level5+ years exp.
4 months ago
Natera logo
Natera

Director, Media Relations and Communications

USA (Remote)

$166K/yr – $207K/yrDirector/Executive8+ years expFull time

Posted 2 months ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Own the media relations program for oncology-focused storytelling, shaping proactive strategy, story development, and high-impact outreach across national, local, and trade outlets.

  • Media strategy and agency performance: define goals, manage deliverables, and optimize external support.
  • Story development and delivery: identify compelling angles from clinical data, patient impact, and milestones; coordinate briefings and interviews.
  • Relations and rapid response: cultivate reporter relationships, field inquiries, and ensure quick, accurate external communications.

Job Description

Responsibilities

  • Build and execute a proactive media strategy
  • Develop and implement a consistent, forward-looking media plan aligned to company priorities, with a strong emphasis on oncology
  • Identify news moments, trends, and story angles that position the company as a leader in its space
  • Drive a steady cadence of high-quality media coverage across national, local, and trade outlets
  • Develop and manage media relationships
  • Build and maintain strong relationships with key reporters, editors, and producers
  • Proactively pitch stories, coordinate briefings, and manage ongoing media engagement
  • Serve as a contact for inbound media inquiries
  • Oversee external PR firm to ensure alignment with strategy, messaging, and priorities
  • Set clear goals, manage deliverables, and hold agency accountable for performance

Requirements

  • Bachelor's degree, with 8-10 years of experience in communications and media relations
  • Proficiency in Microsoft Office Suite, with strong skills in PowerPoint/Google Slides, and familiarity with digital communication tools and platforms.

Preferred

  • Experience in healthcare, biotech, or life sciences strongly preferred, including the ability to communicate complex scientific data
  • Demonstrated success securing media coverage across national, local, and trade outlets, including experience driving broad consumer/patient awareness
  • Strong writing and storytelling skills, with significant experience drafting press materials and media pitches
  • Experience managing external PR agencies and driving results through partners
  • Proven ability to build relationships with reporters and navigate complex, technical subject matter
  • Highly organized, proactive, and comfortable managing multiple priorities simultaneously
  • Ability to operate independently and execute with minimal oversight
  • Executive presence and an entrepreneurial spirit, with the ability to identify areas of opportunity and fill gaps
  • The ability to produce high-quality content under tight deadlines in a fast-paced, dynamic environment
  • Bachelor's degree, with 8-10 years of experience in communications and media relations

Benefits

  • Competitive Benefits - Employee benefits include comprehensive medical, dental, vision, life and disability plans for eligible employees and their dependents.
  • Additionally, Natera employees and their immediate families receive free testing in addition to fertility care benefits.
  • Other benefits include pregnancy and baby bonding leave, 401k benefits, commuter benefits and much more.
  • We also offer a generous employee referral program!
Natera logo

Natera

3.5 Glassdoor

NateraTM is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 250 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California.Please be advised that Natera will only reach out to candidates with an @natera.com email domain. Email communications from all other domain names are not from Natera or its employees and are fraudulent. Natera does not request interviews via text messages and does not ask for personal information until a candidate has engaged with the company and has spoken to a recruiter and the hiring team. Natera takes cyber crimes seriously, and will collaborate with law enforcement authorities to prosecute any related cyber crimes.https://www.natera.com/privacy/

Founded in 2004
Austin, Texas, USA
5.3K employees (230 in marketing)
www.natera.com
61% recommend to a friend
69% CEO approval

Traffic Signals

Monthly Visitors
868.9K
Monthly Google Ads Budget
$22.6K
Traffic Source Mix
Search
34.3%
Direct
59.6%
Referral
4.9%
Social
0.7%
Paid
0.4%

Headcount Trend

Current headcount: ~5.3K

Marketing Team

Marketing Team Size
135 (3% of company)
Median Career Experience
14.5 years
Median Tenure
4.2 years

People

Marketing Leadership

Brian Symmons
Brian Symmons
Senior Vice President, Marketing & Patient Experience
At the company for 6 years 10 months
Patrick Miller
Patrick Miller
Vice President of Marketing, Strategy, & BD - Organ Health
At the company for 11 years 6 months
Keith Hanigan
Keith Hanigan
Vice President Oncology Commercial Marketing
At the company for 4 years 10 months
Wing-Kit Chu
Wing-Kit Chu
Director - NIPT and Hereditary Cancer Marketing
At the company for 4 years 4 months

Funding

Total Funding
$1.2B
Last Raise
$250M
Post IPO Equity, 3 years ago

Funding History

  • Sep 2023
    Post IPO Equity • $250M
  • Nov 2022
    Post IPO Equity • $400.1M
  • Mar 2022
    Post IPO Equity • $5M

Recent News

Natera acquires Foresight Diagnostics for up to $450M
Dec 10, 2025 • MedTech Dive
Wilson Sonsini Advises Foresight Diagnostics on Acquisition by Natera
Dec 9, 2025 • Wilson Sonsini
Natera purchases Foresight Diagnostics
Dec 8, 2025 • Yahoo Finance
Natera buys Foresight Diagnostics in cancer testing deal worth up to $450M
Dec 5, 2025 • Fierce Biotech
Natera Acquires Foresight Diagnostics
Dec 5, 2025 • Contract Pharma
Natera Acquires Foresight Diagnostics
Dec 5, 2025 • Yahoo Finance
Natera to Present 12 Datasets Including >50,000 Patients Featuring Signatera™ at the San Antonio Breast Cancer Symposium
Dec 2, 2025 • Yahoo Finance
Assessing Natera’s Value After 47.6% Rally and New Partnerships in 2025
Nov 27, 2025 • Yahoo Finance
Spotting Winners: Natera (NASDAQ:NTRA) And Immuno-Oncology Stocks In Q3
Nov 19, 2025 • Yahoo Finance
Natera stock hits all-time high of 212.23 USD
Nov 18, 2025 • Investing.com
Does Natera (NTRA) Have a Long Runway For Growth?
Nov 14, 2025 • Yahoo Finance
Natera Integrates with Flatiron Health’s OncoEMR® Platform
Nov 12, 2025 • Yahoo Finance
Natera (NTRA): Valuation Insights Following Strong Q3 Results and Upbeat Guidance Boost
Nov 10, 2025 • Yahoo Finance
Natera Inc (NTRA) Q3 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic Expansions
Nov 7, 2025 • Yahoo Finance
Earnings call transcript: Natera Q3 2025 sees revenue beat, EPS miss
Nov 6, 2025 • Investing.com
Natera Reports Third Quarter 2025 Financial Results
Nov 6, 2025 • Yahoo Finance
Natera (NTRA) Reports Earnings Tomorrow: What To Expect
Nov 4, 2025 • Yahoo Finance
Natera Announces Expansion to 20 Genes for its Fetal Focus™ Single-Gene NIPT
Oct 31, 2025 • Yahoo Finance
Natera to Report its Third Quarter Results on November 6, 2025
Oct 30, 2025 • Yahoo Finance
Natera, known for spotting cancer recurrence, wades into early detection
Oct 29, 2025 • statnews.com
How Recent Developments Are Reshaping the Natera Investment Story
Oct 28, 2025 • Yahoo Finance
Natera (NTRA): Assessing Valuation After Pivotal Clinical Data Boosts FDA Prospects for Signatera
Oct 27, 2025 • Yahoo Finance
Is Natera’s Rally Justified After Soaring 58.5% on Genetic Testing Breakthroughs?
Oct 23, 2025 • simplywall.st
Natera CEO Chapman sells $301k in shares
Oct 22, 2025 • Investing.com
Natera reveals positive results from MIBC clinical trial
Oct 21, 2025 • Clinical Trials Arena
Why Are Natera (NTRA) Shares Soaring Today
Oct 20, 2025 • Yahoo Finance
Natera Named to Fast Company’s Next Big Things in Tech List
Oct 16, 2025 • Yahoo Finance
Natera stock hits all-time high of 183.99 USD
Oct 16, 2025 • Investing.com
Natera stock price target maintained at $200 by Canaccord on MRD leadership
Oct 14, 2025 • Investing.com
Natera Shows Improved Relative Price Performance; Still Shy Of Benchmark
Oct 14, 2025 • Investor's Business Daily
Natera to Host Investor Call on October 23, 2025 to Discuss ESMO Findings
Oct 13, 2025 • Yahoo Finance
Natera to Present 14 Studies at ESMO, Including IMvigor011 Oral Presentation in Presidential Symposium
Oct 12, 2025 • Yahoo Finance
Enrollment Tops 1,600 in Natera’s EXPAND Trial of Single Gene NIPT
Oct 1, 2025 • Yahoo Finance
Natera Announces Publication of Signatera™ Validation Study in Testicular Cancer
Sep 30, 2025 • Yahoo Finance
91.6% Detection Rate: Natera's Breakthrough Study Shows Signatera Test Superior for Testicular Cancer Monitoring
Sep 30, 2025 • Stock Titan
Natera’s Signatera test shows strong results for uterine cancer monitoring
Sep 29, 2025 • Investing.com
Why Natera (NTRA) Stock Is Down Today
Sep 24, 2025 • Yahoo Finance
Natera Insider Sold Shares Worth $9,016,668, According to a Recent SEC Filing
Sep 22, 2025 • MarketScreener
Natera initiated with neutral view at Wells Fargo, here's why
Sep 22, 2025 • thefly.com
Natera Executive Chairman Matthew Rabinowitz Sells 50,000 Shares
Sep 20, 2025 • TradingView
Susan G. Komen® To Host MORE THAN PINK Walk in Oklahoma City This October
Sep 18, 2025 • Morningstar.com
Natera Earns RS Rating Upgrade
Sep 17, 2025 • Investor's Business Daily
Natera Stock Analysis: Why This Cancer Testing Stock Could Triple
Sep 15, 2025 • Trefis
Can Natera Stock Reach $500?
Sep 15, 2025 • Forbes
Why Natera (NTRA) Stock Is Trading Lower Today
Sep 12, 2025 • Yahoo Finance
Asia-Pacific Non-Invasive Prenatal Testing Market Growth and Company Analysis Report 2025-2033 Featuring Eurofins Scientific, F. Hoffmann-La Roche, Invitae, Illumina, Natera, Centogene, and Qiagen
Sep 10, 2025 • Research and Markets
3 Reasons We’re Fans of Natera (NTRA)
Sep 9, 2025 • Yahoo Finance
A Fresh Look at Natera (NTRA) Valuation After Launch of ARCHER Phase III Bladder Cancer Trial
Sep 9, 2025 • simplywall.st
Natera (NTRA): How the ARCHER Trial May Shape Future Valuation After Key Signatera Milestone
Sep 8, 2025 • Yahoo Finance
Natera Executives Conduct Significant Stock Transactions
Sep 6, 2025 • TradingView
Natera CEO Chapman sells $845k in shares
Sep 5, 2025 • Investing.com
Natera Introduces Prenatal Test for Inherited Conditions
Sep 3, 2025 • Medical Product Outsourcing
Natera director Chapman sells $459k in shares
Sep 2, 2025 • Investing.com
Natera: A Buy As Positive Growth And Cashflow Outweigh Unprofitability
Sep 2, 2025 • Seeking Alpha
Breakthrough Cancer Therapies Fuel Regulatory Momentum as Global Market Expands
Sep 2, 2025 • PR Newswire
Breakthrough Cancer Therapies Fuel Regulatory Momentum as Global Market Expands
Sep 2, 2025 • PR Newswire UK
Breakthrough Cancer Therapies Fuel Regulatory Momentum as Global Market Expands
Sep 2, 2025 • Canada NewsWire
Natera (NTRA) Provides an Update on its Intellectual Property Litigation With NeoGenomics
Sep 1, 2025 • Yahoo Finance
Optimistic Investors Push Natera, Inc. (NASDAQ:NTRA) Shares Up 25% But Growth Is Lacking
Aug 31, 2025 • simplywall.st
NeoGenomics Scores Win In Natera DNA Test Patent Suit
Aug 29, 2025 • Law360
Natera’s Signatera test to be used in Phase III bladder cancer trial
Aug 29, 2025 • Medical Device Network
Court Rules for NeoGenomics in Patent Infringement Lawsuit Against Natera
Aug 29, 2025 • Business Wire
Why Natera (NTRA) Stock Is Down Today
Aug 29, 2025 • Yahoo Finance
NeoGenomics Gains 'Unexpected' Win As Court Rejects Natera Claims
Aug 29, 2025 • Benzinga.com
NeoGenomics Says Court Decides to Invalidate Natera's Asserted Patents; Shares up Pre-Bell
Aug 29, 2025 • MarketScreener
NeoGenomics announces court ruling in its favor in lawsuit against Natera
Aug 29, 2025 • thefly.com
SentinelOne, Autodesk, Dollar Tree
Aug 29, 2025 • Reuters
Natera Provides Update on Patent Litigation with NeoGenomics
Aug 29, 2025 • Business Wire
Sector Update: Health Care Stocks Decline Premarket Friday
Aug 29, 2025 • MarketScreener
Why Natera (NTRA) Stock Is Up Today
Aug 28, 2025 • Yahoo Finance
3rd Circ. Agrees Natera Doesn't Owe $45M In False Ad Fight
Aug 28, 2025 • Law360
Natera Shares Rise on the Launch of AI Platform for Precision Oncology
Aug 25, 2025 • Yahoo Finance
Natera to Present Signatera™ Data at the IASLC World Conference on Lung Cancer
Aug 25, 2025 • BioSpace
Natera Technology Featured in 300+ Peer-Reviewed Publications, Underscoring Scientific Leadership in Precision Medicine
Aug 22, 2025 • Business Wire
Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation
Aug 22, 2025 • Yahoo Finance
250,000+ Tumor Exomes: Natera's Massive AI Platform Could Transform Cancer Treatment Decisions
Aug 22, 2025 • Stock Titan
Natera Introduces AI Models to Speed Up Diagnostic and Therapeutic Innovation
Aug 22, 2025 • MarketScreener
Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation
Aug 22, 2025 • Morningstar.com
Natera Technology Featured in 300+ Peer-Reviewed Publications, Underscoring Scientific Leadership in Precision Medicine
Aug 22, 2025 • BioSpace
Precision Genomic Testing Market Projected to Reach $23.11 Billion with 11.4% CAGR by 2029
Aug 22, 2025 • EIN Presswire
New Products Posted to GenomeWeb: Natera, 10x Genomics, Twist Bioscience, More
Aug 22, 2025 • GenomeWeb
Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation
Aug 22, 2025 • MarketScreener
Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation
Aug 22, 2025 • MarketScreener
Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation
Aug 22, 2025 • Business Wire
Natera (NTRA) Reports Positive Phase III Trial Results in Muscle-Invasive Bladder Cancer
Aug 19, 2025 • simplywall.st
Susan G. Komen® To Host 2025 Northeast Ohio MORE THAN PINK Walk This September
Aug 19, 2025 • Business Wire
Natera Reports Improved Survival in Signatera-Positive Bladder Cancer Patients Receiving Tecentriq
Aug 19, 2025 • GenomeWeb
Natera pursues ctDNA assay approval after Phase III victory
Aug 18, 2025 • Clinical Trials Arena
IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit
Aug 18, 2025 • MarketScreener
IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit
Aug 18, 2025 • Business Wire
IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit
Aug 18, 2025 • BioSpace
Druckenmiller’s Equity Bets Hit Seven-Year Peak
Aug 18, 2025 • Institutional Investor
Natera Says Bladder Cancer Phase III Study Shows Positive Results
Aug 18, 2025 • MarketScreener
Natera says IMvigor011 bladder cancer trial achieves positive results
Aug 18, 2025 • thefly.com
Natera (NTRA) Is Up 7.3% After Raising 2025 Revenue Guidance and Launching Fetal Focus Test Has The Bull Case Changed?
Aug 17, 2025 • Yahoo Finance
LabCorp Fails to Block Natera Patent-Invalidity Claims Pre-Trial
Aug 15, 2025 • Bloomberg Law News
New Products Posted to GenomeWeb: Natera, Bionano Genomics, Streck
Aug 15, 2025 • GenomeWeb
5 Revealing Analyst Questions From Natera’s Q2 Earnings Call
Aug 13, 2025 • Yahoo Finance
Transcript : Natera, Inc. Presents at Canaccord Genuity?s 45th Annual Growth Conference, Aug-12-2025 02
Aug 13, 2025 • MarketScreener
Natera Insider Sold Shares Worth $958,059, According to a Recent SEC Filing
Aug 13, 2025 • MarketScreener